| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
There was a positive correlation between the clinical efficacy by gemcitabine and the expression of deoxycytidine kinase in pancreatic cancer. The majority of pancreatic cancers showed overexpression of HER2 and/or EGFR. Consequently, lapatinib, a molecular targeting agent for both of HER2 and EGFR, may be effective for pancreatic cancer. In vitro and in vivo experimental results demonstrated the substantial anti-tumor effect for pancreatic cancer by lapatinib alone and combined with S-1. It was suggested that the anti-tumor effect of lapatinib was associated with HER2 expression.
|
